These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15500557)

  • 21. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era.
    Kramer JR; Giordano TP; Souchek J; El-Serag HB
    J Hepatol; 2005 Mar; 42(3):309-14. PubMed ID: 15710213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.
    Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW
    J Viral Hepat; 2011 Jan; 18(1):32-41. PubMed ID: 20196806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
    AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of viral hepatitis on HIV infection.
    Rockstroh JK
    J Hepatol; 2006; 44(1 Suppl):S25-7. PubMed ID: 16338020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV and hepatitis C coinfection within the CAESAR study.
    Amin J; Kaye M; Skidmore S; Pillay D; Cooper DA; Dore GJ
    HIV Med; 2004 May; 5(3):174-9. PubMed ID: 15139984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of highly active anti-retroviral therapy and hepatitis C virus co-infection on serum levels of pro-inflammatory and immunoregulatory cytokines in human immunodeficiency virus-1-infected individuals.
    Tornero C; Alberola J; Tamarit A; Navarro D
    Clin Microbiol Infect; 2006 Jun; 12(6):555-60. PubMed ID: 16700705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
    Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
    Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
    Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
    J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to first-line antiretroviral treatment among human immunodeficiency virus-infected patients with and without a history of injecting drug use in Indonesia.
    Wisaksana R; Indrati AK; Fibriani A; Rogayah E; Sudjana P; Djajakusumah TS; Sumantri R; Alisjahbana B; van der Ven A; van Crevel R
    Addiction; 2010 Jun; 105(6):1055-61. PubMed ID: 20331555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study.
    Omland LH; Jepsen P; Weis N; Christensen PB; Laursen AL; Nielsen H; Krarup H; Sørensen HT; Obel N
    J Viral Hepat; 2010 Apr; 17(4):261-8. PubMed ID: 19709359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs.
    Resti M; Azzari C; Galli L; Zuin G; Giacchino R; Bortolotti F; Marcellini M; Moriondo M; de Martino M; Vierucci A;
    J Infect Dis; 2002 Mar; 185(5):567-72. PubMed ID: 11865412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus reinfection in injection drug users.
    Grebely J; Conway B; Raffa JD; Lai C; Krajden M; Tyndall MW
    Hepatology; 2006 Nov; 44(5):1139-45. PubMed ID: 17058216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
    Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
    J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.